Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: Insight into mechanisms of MOG-induced EAE

被引:66
作者
Eltayeb, Sana
Berg, Anna-Lena [1 ]
Lassmann, Hans
Wallstrom, Erik
Nilsson, Maria
Olsson, Tomas
Ericsson-Dahlstrand, Anders
Sunnemark, Dan
机构
[1] AstraZeneca R&D Sodertalje, Safety Assessment, Dept Pathol, S-15185 Sodertalje, Sweden
[2] Karolinska Inst, Neuroimmunol Unit, Ctr Mol Med, Dept Clin Neurosci, S-17176 Stockholm, Sweden
[3] Univ Vienna, Brain Res Inst, Vienna, Austria
[4] AstraZeneca R&D Sodertalje, Dept Dis Biol, Local Discovery Res Area CNS & Pain Control, S-15185 Sodertalje, Sweden
关键词
D O I
10.1186/1742-2094-4-14
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The CC chemokine receptors CCR1, CCR2 and CCR5 are critical for the recruitment of mononuclear phagocytes to the central nervous system ( CNS) in multiple sclerosis ( MS) and other neuroinflammatory diseases. Mononuclear phagocytes are effector cells capable of phagocytosing myelin and damaging axons. In this study, we characterize the regional, temporal and cellular expression of CCR1, CCR2 and CCR5 mRNA in the spinal cord of rats with myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis ( MOG-EAE). While resembling human MS, this animal model allows unique access to CNS-tissue from various time-points of relapsing neuroinflammation and from various lesional stages: early active, late active, and inactive completely demyelinated lesions. Methods: The expression of CCR1, CCR2 and CCR5 mRNA was studied with in situ hybridization using radio labelled cRNA probes in combination with immunohistochemical staining for phenotypic cell markers. Spinal cord sections from healthy rats and rats with MOG-EAE ( acute phase, remission phase, relapse phase) were analysed. In defined lesion stages, the number of cells expressing CCR1, CCR2 and CCR5 mRNA was determined. Data were statistically analysed by the nonparametric Mann-Whitney U test. Results: In MOG-EAE rats, extensive up-regulation of CCR1 and CCR5 mRNA, and moderate up-regulation of CCR2 mRNA, was found in the spinal cord during episodes of active inflammation and demyelination. Double staining with phenotypic cell markers identified the chemokine receptor mRNA-expressing cells as macrophages/ microglia. Expression of all three receptors was substantially reduced during clinical remission, coinciding with diminished inflammation and demyelination in the spinal cord. Healthy control rats did not show any detectable expression of CCR1, CCR2 or CCR5 mRNA in the spinal cord. Conclusion: Our results demonstrate that the acute and chronic-relapsing phases of MOG-EAE are associated with distinct expression of CCR1, CCR2, and CCR5 mRNA by cells of the macrophage/ microglia lineage within the CNS lesions. These data support the notion that CCR1, CCR2 and CCR5 mediate recruitment of both infiltrating d macrophages and resident microglia to sites of CNS inflammation. Detailed knowledge of expression patterns is crucial for the understanding of therapeutic modulation and the validation of CCR1, CCR2 and CCR5 as feasible targets for therapeutic intervention in MS.
引用
收藏
页数:13
相关论文
共 86 条
[1]   Chemokines: Leucocyte recruitment and activation cytokines [J].
Adams, DH ;
Lloyd, AR .
LANCET, 1997, 349 (9050) :490-495
[2]  
AMOR S, 1994, J IMMUNOL, V153, P4349
[3]   CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions [J].
Balashov, KE ;
Rottman, JB ;
Weiner, HL ;
Hancock, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6873-6878
[4]   CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis [J].
Barcellos, LF ;
Schito, AM ;
Rimmler, JB ;
Vittinghoff, E ;
Shih, A ;
Lincoln, R ;
Callier, S ;
Elkins, MK ;
Goodkin, DE ;
Haines, JL ;
Pericak-Vance, MA ;
Hauser, SL ;
Oksenberg, JR .
IMMUNOGENETICS, 2000, 51 (4-5) :281-288
[5]   The CCR5 deletion mutation fails to protect against multiple sclerosis [J].
Bennetts, BH ;
Teutsch, SM ;
Buhler, MM ;
Heard, RNS ;
Stewart, GJ .
HUMAN IMMUNOLOGY, 1997, 58 (01) :52-59
[6]   Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice [J].
Boring, L ;
Gosling, J ;
Chensue, SW ;
Kunkel, SL ;
Farese, RV ;
Broxmeyer, HE ;
Charo, IF .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) :2552-2561
[7]   Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344 [J].
Brodmerkel, CM ;
Huber, R ;
Covington, M ;
Diamond, S ;
Hall, L ;
Collins, R ;
Leffet, L ;
Gallagher, K ;
Feldman, P ;
Collier, P ;
Stow, M ;
Gu, XM ;
Baribaud, F ;
Shin, N ;
Thomas, B ;
Burn, T ;
Hollis, G ;
Yeleswaram, S ;
Solomon, K ;
Friedman, S ;
Wang, AL ;
Xue, CB ;
Newton, RC ;
Scherle, P ;
Vaddi, K .
JOURNAL OF IMMUNOLOGY, 2005, 175 (08) :5370-5378
[8]   Mechanisms of immune injury in multiple sclerosis [J].
Brosnan, CF ;
Raine, CS .
BRAIN PATHOLOGY, 1996, 6 (03) :243-257
[9]  
Bruck W, 1996, IMMUNOBIOLOGY, V195, P588
[10]   MONOCYTE-MACROPHAGE DIFFERENTIATION IN EARLY MULTIPLE-SCLEROSIS LESIONS [J].
BRUCK, W ;
PORADA, P ;
POSER, S ;
RIECKMANN, P ;
HANEFELD, F ;
KRETZSCHMAR, HA ;
LASSMANN, H .
ANNALS OF NEUROLOGY, 1995, 38 (05) :788-796